CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jones, J. M.
Right arrow Articles by Donehower, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jones, J. M.
Right arrow Articles by Donehower, L. A.
Cell Growth & Differentiation Vol. 10, 213-222, April 1999
© 1999 American Association for Cancer Research

Heterozygosity of p21WAF1/CIP1 Enhances Tumor Cell Proliferation and Cyclin D1-associated Kinase Activity in a Murine Mammary Cancer Model1

Jeffrey M. Jones, Xian-Shu Cui, Daniel Medina and Lawrence A. Donehower2

Division of Molecular Virology [J. M. J., X-S. C., L. A. D.] and Department of Cell Biology [D. M., L. A. D.], Baylor College of Medicine, Houston, Texas 77030

The p21WAF1/CIP1 cyclin-dependent kinase (cdk) inhibitor is a regulator of the G1-S cell cycle checkpoint. Despite the importance of p21 in cell cycle inhibition, its role as a tumor suppressor is uncertain. p21 mutations are infrequent in human tumors, and p21 null mice exhibit no increased tumor incidence. To ascertain whether p21 could influence tumor formation or progression in the context of other oncogenic stimuli, we crossed p21-deficient mice with mammary tumor susceptible Wnt-1 transgenic mice. The p21+/+, p21+/-, and p21-/- Wnt-1 transgenic female offspring were monitored for mammary tumor incidence and growth rates. p21 status had no effect on the age at which mammary tumors formed. However, p21+/- mammary tumors grew significantly faster than p21+/+ and p21-/- mammary tumors. The increased growth rates were confirmed by mitotic index counts and by BrdUrd labelling assays, indicating that a significantly higher percentage of p21+/- tumor cells were in S phase and mitosis than their p21+/+ and p21-/- counterparts. Moreover, cyclin D1-associated phosphorylation of retinoblastoma protein was significantly increased in p21+/- tumor lysates compared with p21+/+ and p21-/- lysates. These results are consistent with data indicating that reduced levels of p21 can facilitate cyclin/cdk complex formation while enhancing cdk activity. Thus, a reduction of p21 dosage may promote tumor progression in the presence of other oncogenic initiators. The dependence of p21 on prior oncogenic stimuli for its tumor-promoting activities suggests that it may behave as a tumor modifier gene rather than as a tumor suppressor gene.




This article has been cited by other articles:


Home page
J Biol ChemHome page
E. Hukkelhoven, Y. Liu, N. Yeh, D. Ciznadija, S. W. Blain, and A. Koff
Tyrosine Phosphorylation of the p21 Cyclin-dependent Kinase Inhibitor Facilitates the Development of Proneural Glioma
J. Biol. Chem., November 9, 2012; 287(46): 38523 - 38530.
[Abstract] [Full Text] [PDF]


Home page
EMBO J.Home page
Y. Liu, N. Yeh, X.-H. Zhu, M. Leversha, C. Cordon-Cardo, R. Ghossein, B. Singh, E. Holland, and A. Koff
Somatic cell type specific gene transfer reveals a tumor-promoting function for p21Waf1/Cip1
EMBO J., November 14, 2007; 26(22): 4683 - 4693.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Law, E. Forrester, A. Chytil, P. Corsino, G. Green, B. Davis, T. Rowe, and B. Law
Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes
Cancer Res., January 15, 2006; 66(2): 1070 - 1080.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
R. J. Jackson, R. W. Engelman, D. Coppola, A. B. Cantor, W. Wharton, and W. J. Pledger
p21Cip1 Nullizygosity Increases Tumor Metastasis in Irradiated Mice
Cancer Res., June 15, 2003; 63(12): 3021 - 3025.
[Abstract] [Full Text] [PDF]


Home page
EMBO J.Home page
M. T. Scott, A. Ingram, and K. L. Ball
PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumour modifier protein
EMBO J., December 16, 2002; 21(24): 6771 - 6780.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. J. Bearss, R. J. Lee, D. A. Troyer, R. G. Pestell, and J. J. Windle
Differential Effects of p21WAF1/CIP1 Deficiency on MMTV-ras and MMTV-myc Mammary Tumor Properties
Cancer Res., April 1, 2002; 62(7): 2077 - 2084.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
U-J Gohring, A Bersch, M Becker, W Neuhaus, and T Schondorf
p21waf correlates with DNA replication but not with prognosis in invasive breast cancer
J. Clin. Pathol., November 1, 2001; 54(11): 866 - 870.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
Q. Liu, S. Guntuku, X.-S. Cui, S. Matsuoka, D. Cortez, K. Tamai, G. Luo, S. Carattini-Rivera, F. DeMayo, A. Bradley, et al.
Chk1 is an essential kinase that is regulated by Atr and required for the G2/M DNA damage checkpoint
Genes & Dev., June 15, 2000; 14(12): 1448 - 1459.
[Abstract] [Full Text]


Home page
J Biol ChemHome page
M. T. Scott, N. Morrice, and K. L. Ball
Reversible Phosphorylation at the C-terminal Regulatory Domain of p21Waf1/Cip1 Modulates Proliferating Cell Nuclear Antigen Binding
J. Biol. Chem., April 14, 2000; 275(15): 11529 - 11537.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1999 by the American Association of Cancer Research.